ArticleMissouri medicine
New developments in the surgical management of end-stage heart failure.
Article in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is a major healthcare problem associated with morbidity and mortality. Despite progress in treatments, the prognosis of heart failure remains poor. Standard treatments for heart failure include medical therapy, resynchronization therapy, and cardiac surgery. Heart failure teams providing guideline based care assist in the optimal management for advanced heart failure. Progression of heart failure despite optimal management may be treated with heart transplant. In non-transplant eligible patients, implantable left ventricular assist devices (LVADs) may improve patients 'quality of life and survival. Advances in LVADs, including smaller size, increased device durability, and (near) totally implantable devices, may enable LVADs to become an option in less sick patients. Evolving therapeutics such as stem cells and novel therapeutics may be combined with LVADs to allow myocardial recovery. This article will review current and developing strategies in the surgical management of heart failure with an emphasis on LVAD therapy.
Indexed as
Identifiers
22953592PMC6179777W2399762589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.